Performance of the immunochemical fecal occult blood test in predicting lesions in the lower gastrointestinal tract

CMAJ. Canadian Medical Association Journal

Volumn 183, Issue 13, 2011, Pages 1474-1481

  Chiang, Tsung Hsien ^a,b   Lee, Yi Chia ^a,c   Tu, Chia Hung ^a,c   Chiu, Han Mo ^a,c   Wu, Ming Shiang ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; HEMOGLOBIN;

ADULT; AGED; ARTICLE; COLON ADENOMA; COLON CANCER; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DRUG USE; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGUS CANCER; FALSE POSITIVE RESULT; FEMALE; HELICOBACTER INFECTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOHISTOCHEMISTRY; INTESTINE INJURY; LOWER GASTROINTESTINAL TRACT LESION; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD TEST; POPULATION RESEARCH; PREDICTIVE VALUE; PROGNOSIS; RISK ASSESSMENT; SCREENING TEST; SENSITIVITY AND SPECIFICITY; STOMACH CANCER;

EID: 80053083133     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.101248     Document Type: Article

References (39)

1. American Gastroenterological Association medical position statement: evaluation and management of occult and obscure gastrointestinal bleeding. Gastroenterology 2000;118:197-201.
2. Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997; 112:594-642. (Pubitemid 27078848)
3. Davila RE, Rajan E, Baron TH, et al.; Standards of Practice Committee, American Society for Gastrointestinal Endoscopy. ASGE guideline: colorectal cancer screening and surveillance. Gastrointest Endosc 2006;63:546-57.
4. Bini EJ. Use of upper endoscopy to evaluate patients with a positive fecal occult blood test and negative colonoscopy: Is it appropriate? Dig Liver Dis 2006;38:507-10. (Pubitemid 44356231)
5. Geller AJ, Kolts BE, Achem SR, et al. The high frequency of upper gastrointestinal pathology in patients with fecal occult blood and colon polyps. Am J Gastroenterol 1993;88:1184-7. (Pubitemid 23219710)
6. Alemayehu G, Järnerot G. Same-day upper and lower endoscopy in patients with occult bleeding, melena, hematochezia, and/or microcytic anemia. A retrospective study of 224 patients. Scand J Gastroenterol 1993;28:667-72. (Pubitemid 23231984)
7. Rockey DC, Koch J, Cello JP, et al. Relative frequency of upper gastrointestinal and colonic lesions in patients with positive fecal occult-blood tests. N Engl J Med 1998;339:153-9. (Pubitemid 28328479)
8. Bini EJ, Rajapaksa RC, Valdes MT, et al. Is upper gastrointestinal endoscopy indicated in asymptomatic patients with a positive fecal occult blood test and negative colonoscopy? Am J Med 1999; 106:613-8. (Pubitemid 29279296)
9. Velez JP, Schwesinger WH, Stauffer J, et al. Bidirectional endoscopy in patients with fecal occult blood. Surg Endosc 2002; 16:117-20.
10. Zuckerman G, Benitez J. A prospective study of bidirectional endoscopy (colonoscopy and upper endoscopy) in the evaluation of patients with occult gastrointestinal bleeding. Am J Gastroenterol 1992;87:62-6.
11. Hsia PC, Al-Kawas FH. Yield of upper endoscopy in the evaluation of asymptomatic patients with Hemoccult-positive stool after a negative colonoscopy. Am J Gastroenterol 1992; 87: 1571-4.
12. Thomas WM, Hardcastle JD. Role of upper gastrointestinal investigation in a screening study for colorectal neoplasia. Gut 1990;31:1294-7.
13. Urquhart J, Eisen G, Faigel DO, et al. A closer look at same-day bidirectional endoscopy. Gastrointest Endosc 2009;69:271-7.
14. Chen YK, Gladden DR, Kestenbaum DJ, et al. Is there a role for upper gastrointestinal endoscopy in the evaluation of patients with occult blood-positive stool and negative colonoscopy? Am J Gastroenterol 1993;88:2026-9. (Pubitemid 23352165)
15. Rasmussen M, Kronborg O. Upper gastrointestinal cancer in a population-based screening program with fecal occult blood test for colorectal cancer. Scand J Gastroenterol 2002;37:95-8. (Pubitemid 34074740)
16. Ali M, Yaqub M, Haider Z, et al. Yield of dual endoscopy for positive fecal occult blood test. Am J Gastroenterol 2003;98:82-5. (Pubitemid 36135174)
17. Zappa M, Visioli CB, Ciatto S, et al. Gastric cancer after positive screening fecal occult blood testing and negative assessment. Dig Liver Dis 2007;39:321-6. (Pubitemid 46432240)
18. Bini EJ, Rajapaksa RC, Weinshel EH. Positive predictive value of fecal occult blood testing in persons taking warfarin. Am J Gastroenterol 2005;100:1586-92. (Pubitemid 41032368)
19. Stray N, Weberg R. A prospective study of same day bi- directional endoscopy in the evaluation of patients with occult gastrointestinal bleeding. Scand J Gastroenterol 2006;41:844-50. (Pubitemid 43941245)
20. Hisamuddin K, Mowat NA, Phull PS. Endoscopic findings in the upper gastrointestinal tract of faecal occult blood-positive, colonoscopy-negative patients. Dig Liver Dis 2006;38:503-7. (Pubitemid 44356224)
21. Levi Z, Vilkin A, Niv Y. Esophago-gastro-duodenoscopy is not indicated in patients with positive immunochemical test and non-explanatory colonoscopy. Eur J Gastroenterol Hepatol 2010; 22: 1431-4.
22. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008;58:130-60. (Pubitemid 351830299)
23. Cancer Registry annual report, 2008. Taiwan: Bureau of Health Promotion, Department of Health, the Executive Yuan; 2010.
24. Chiu HM, Lin JT, Shun CT, et al. Association of metabolic syndrome with proximal and synchronous colorectal neoplasm. Clin Gastroenterol Hepatol 2007;5:221-9.
25. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999;45:172-80. (Pubitemid 29333764)
26. Morikawa T, Kato J, Yamaji Y, et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005; 129: 422-8. (Pubitemid 41096630)
27. Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007;99: 1462-70.
28. Chiu HM, Lin JT, Chen CC, et al. Prevalence and characteristics of nonpolypoid colorectal neoplasm in an asymptomatic and average-risk Chinese population. Clin Gastroenterol Hepatol 2009;7:463-70.
29. Levi Z, Rozen P, Hazazi R, et al. Sensitivity, but not specificity, of a quantitative immunochemical fecal occult blood test for neoplasia is slightly increased by the use of low-dose aspirin, NSAIDs, and anticoagulants. Am J Gastroenterol 2009;104: 933-8.
30. Brenner H, Tao S, Haug U. Low-dose aspirin use and performance of immunochemical fecal occult blood tests. JAMA 2010;304:2513-20.
31. Van Rossum LG, Van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008;135:82-90. (Pubitemid 351899018)
32. Wong BC, Wong WM, Cheung KL, et al. A sensitive guaiac faecal occult blood test is less useful than an immunochemical test for colorectal cancer screening in a Chinese population. Aliment Pharmacol Ther 2003;18:941-6. (Pubitemid 37346679)
33. Wong WM, Lam SK, Cheung KL, et al. Evaluation of an automated immunochemical fecal occult blood test for colorectal neoplasia detection in a Chinese population. Cancer 2003; 97: 2420-4. (Pubitemid 36542480)
34. Chen LS, Liao CS, Chang SH, et al. Cost-effectiveness analysis for determining optimal cut-off of immunochemical faecal occult blood test for population-based colorectal cancer screening (KCIS 16). J Med Screen 2007;14:191-9.
35. Mandelli G, Radaelli F, Paggi S, et al. Anticoagulant or aspirin treatment does not affect the positive predictive value of an immunological fecal occult blood test in patients undergoing colorectal cancer screening: results from a nested in a cohort case-control study. Eur J Gastroenterol Hepatol 2011;23:323-6.
36. Ahlquist DA. Next-generation stool DNA testing: expanding the scope. Gastroenterology 2009;136:2068-73.
37. Shimoyama T, Oyama T, Matsuzaka M, et al. Comparison of a stool antigen test and serology for the diagnosis of Helicobacter pylori infection in mass survey. Helicobacter 2009;14:87-90.
38. Sung JJ, Lau JY, Goh KL, et al.; Asia Pacific Working Group on Colorectal Cancer. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol 2005;6:871-6. (Pubitemid 41614799)
39. Leung WK, Wu MS, Kakugawa Y, et al.; Asia Pacific Working Group on Gastric Cancer. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 2008;9:279-87. (Pubitemid 351722947)